{"DataElement":{"publicId":"3587247","version":"1","preferredName":"Diabetes Mellitus Treatment Type","preferredDefinition":"Types of treatment used to manage Diabetes.","longName":"3587239v1.0:3587242v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3587239","version":"1","preferredName":"Diabetes Mellitus Treatment","preferredDefinition":"Related to the treatment of diabetes mellitus, a metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization","longName":"2442242v1.0:2187763v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2442242","version":"1","preferredName":"Diabetes Mellitus","preferredDefinition":"(dye-a-BEE-teez) A disease in which the body does not properly control the amount of sugar in the blood. As a result, the level of sugar in the blood is too high. This disease occurs when the body does not produce enough insulin or does not use it properly.","longName":"C2985","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diabetes Mellitus","conceptCode":"C2985","definition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"09046428-4DAC-6C1D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-29","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-12-29","modifiedBy":"ONEDATA","dateModified":"2005-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2187763","version":"1","preferredName":"Treatment","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"Treatment","context":"CCR","contextVersion":"1","Concepts":[{"longName":"Treatment","conceptCode":"C0087111","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E14FFC6A-9E06-327A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-08-13","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C91B83A2-A0FD-517B-E040-BB89AD4321CE","latestVersionIndicator":"Yes","beginDate":"2012-09-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2012-09-07","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"created for UAMS 9/7/12 cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3587242","version":"1","preferredName":"Diabetes Mellitus Therapeutic Procedure Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process. A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","longName":"3587242v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Diet","valueDescription":"Special Diet Therapy","ValueMeaning":{"publicId":"3587244","version":"1","preferredName":"Special Diet Therapy","longName":"3587244","preferredDefinition":"A form of therapy which includes dietary approaches and special diets that are applied as alternative therapies for risk factors or chronic disease in general.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Special Diet Therapy","conceptCode":"C15383","definition":"A form of therapy which includes dietary approaches and special diets that are applied as alternative therapies for risk factors or chronic disease in general.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C91B83A2-A168-517B-E040-BB89AD4321CE","latestVersionIndicator":"Yes","beginDate":"2012-09-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2012-09-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C91B83A2-A181-517B-E040-BB89AD4321CE","beginDate":"2012-09-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2012-09-07","modifiedBy":"ONEDATA","dateModified":"2012-09-07","deletedIndicator":"No"},{"value":"Oral Hypoglycemic","valueDescription":"Oral Non-insulin Hypoglycemic","ValueMeaning":{"publicId":"3587246","version":"1","preferredName":"Oral Non-insulin Hypoglycemic","longName":"3587246","preferredDefinition":"Oral; of, or relating to, or affecting, or for use in the mouth.: Any substance, other than insulin, used to treat hyperglycemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral","conceptCode":"C25311","definition":"Of, or relating to, or affecting, or for use in the mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Non-insulin Hypoglycemic","conceptCode":"C80511","definition":"Any substance, other than insulin, used to treat hyperglycemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C91B83A2-A18F-517B-E040-BB89AD4321CE","latestVersionIndicator":"Yes","beginDate":"2012-09-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2012-09-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C91B83A2-A1A8-517B-E040-BB89AD4321CE","beginDate":"2012-09-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2012-09-07","modifiedBy":"ONEDATA","dateModified":"2012-09-07","deletedIndicator":"No"},{"value":"Insulin","valueDescription":"Insulin","ValueMeaning":{"publicId":"2561935","version":"1","preferredName":"Insulin","longName":"2561935","preferredDefinition":"(IN-su-lin) A hormone made by the islet cells of the pancreas. Insulin controls the amount of sugar in the blood by moving it into the cells, where it can be used by the body for energy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin","conceptCode":"C2271","definition":"Insulin (51 aa, ~6 kDa) is encoded by the human INS gene. This protein is involved in the direct regulation of glucose metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BEFC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-22","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-22","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C91B83A2-A1B2-517B-E040-BB89AD4321CE","beginDate":"2012-09-07","endDate":"2018-01-31","createdBy":"RODGERSC","dateCreated":"2012-09-07","modifiedBy":"COOPERM","dateModified":"2018-01-31","deletedIndicator":"No"},{"value":"Other, specify","valueDescription":"Specify Other","ValueMeaning":{"publicId":"4888051","version":"1","preferredName":"Specify Other","longName":"4888051","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"195A90B1-87F5-D292-E050-BB89AD432B03","latestVersionIndicator":"Yes","beginDate":"2015-06-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59A82CBF-5FC0-136A-E053-F662850A73DE","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"ONEDATA","dateModified":"2017-09-20","deletedIndicator":"No"},{"value":"Alpha-glucosidase inhibitor","valueDescription":"Alpha-glucosidase inhibitor","ValueMeaning":{"publicId":"5982794","version":"1","preferredName":"Alpha-glucosidase inhibitor","longName":"5982794","preferredDefinition":"Any agent that inhibits the enzyme alpha-glucosidase located in the intestines. This prevents the breakdown of complex carbohydrates to glucose and other monosaccharides, which results in decreased intestinal absorption of monosaccharides.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-glucosidase Inhibitor","conceptCode":"C139651","definition":"Any agent that inhibits the enzyme alpha-glucosidase located in the intestines. This prevents the breakdown of complex carbohydrates to glucose and other monosaccharides, which results in decreased intestinal absorption of monosaccharides.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59A82CBF-5FCA-136A-E053-F662850A73DE","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59A82CBF-5FE3-136A-E053-F662850A73DE","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"ONEDATA","dateModified":"2017-09-20","deletedIndicator":"No"},{"value":"Thiazolidinedione","valueDescription":"Thiazolidinedione Antidiabetic Agent","ValueMeaning":{"publicId":"5982795","version":"1","preferredName":"Thiazolidinedione Antidiabetic Agent","longName":"5982795","preferredDefinition":"Any antidiabetic agent with the glitazone (thiazolidinedione) base structure with antihyperglycemic activity. Glitazone antidiabetic agents selectively bind to and stimulate the nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma. This results in the selective transcription of a number of insulin-sensitive genes involved in glucose metabolism. This eventually enhances insulin sensitivity, reduces insulin resistance and decreases hepatic gluconeogenesis. PPARs function as transcription factors that regulate expressions of genes involved in cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), as well as tumorigenesis; PPARgamma is expressed at high levels in adipose tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thiazolidinedione Antidiabetic Agent","conceptCode":"C98241","definition":"Any antidiabetic agent with the glitazone (thiazolidinedione) base structure with antihyperglycemic activity. Glitazone antidiabetic agents selectively bind to and stimulate the nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma. This results in the selective transcription of a number of insulin-sensitive genes involved in glucose metabolism. This eventually enhances insulin sensitivity, reduces insulin resistance and decreases hepatic gluconeogenesis. PPARs function as transcription factors that regulate expressions of genes involved in cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), as well as tumorigenesis; PPARgamma is expressed at high levels in adipose tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59A82CBF-5FED-136A-E053-F662850A73DE","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59A82CBF-6006-136A-E053-F662850A73DE","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"ONEDATA","dateModified":"2017-09-20","deletedIndicator":"No"},{"value":"Sulfonylurea","valueDescription":"Sulfonylurea Antidiabetic Agent","ValueMeaning":{"publicId":"5982797","version":"1","preferredName":"Sulfonylurea Antidiabetic Agent","longName":"5982797","preferredDefinition":"Sulfonamide urea derivatives with antihyperglycemic activity. Sulphonylurea antidiabetic agents bind to sulfonylurea receptor type 1 (SUR1), the subunit of ATP-sensitive inwardly-rectifier potassium (IKATP) channels on the membranes of pancreatic beta cells, thereby blocking the inward current flow (influx) of positively charged K+ ions into the cell. This results in tonic membrane depolarization, and induces a calcium ion influx through voltage-sensitive calcium channels; increased intracellular calcium ion levels trigger exocytosis of insulin-containing granules. This eventually induces secretion of insulin. The IKATP channels found in pancreatic islets are complexes of four IKATP 6.2 and four SUR1 subunits. In addition, some sulfonylureas of larger molecular size may increase the sensitivity of peripheral tissues to insulin mediated through peroxisome proliferator-activated receptor gamma (PPARgamma).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sulfonylurea Antidiabetic Agent","conceptCode":"C97936","definition":"Sulfonamide urea derivatives with antihyperglycemic activity. Sulphonylurea antidiabetic agents bind to sulfonylurea receptor type 1 (SUR1), the subunit of ATP-sensitive inwardly-rectifier potassium (IKATP) channels on the membranes of pancreatic beta cells, thereby blocking the inward current flow (influx) of positively charged K+ ions into the cell. This results in tonic membrane depolarization, and induces a calcium ion influx through voltage-sensitive calcium channels; increased intracellular calcium ion levels trigger exocytosis of insulin-containing granules. This eventually induces secretion of insulin. The IKATP channels found in pancreatic islets are complexes of four IKATP 6.2 and four SUR1 subunits. In addition, some sulfonylureas of larger molecular size may increase the sensitivity of peripheral tissues to insulin mediated through peroxisome proliferator-activated receptor gamma (PPARgamma).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59A82CBF-6013-136A-E053-F662850A73DE","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59A82CBF-602C-136A-E053-F662850A73DE","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"ONEDATA","dateModified":"2017-09-20","deletedIndicator":"No"},{"value":"Biguanide","valueDescription":"Biguanide Antidiabetic Agent","ValueMeaning":{"publicId":"5982799","version":"1","preferredName":"Biguanide Antidiabetic Agent","longName":"5982799","preferredDefinition":"Any antidiabetic agent with the biguanide base structure or phenformin derivatives with antihyperglycemic activity. Biguanide antidiabetic agents activate AMP-activated protein kinase (AMPK) resulting in decreased glucose production in the liver, increased peripheral glucose uptake and improved utilization of glucose. Biguanide-based antidiabetic agents do not cause hypoglycemia. In addition, biguanide antidiabetics decrease absorption of glucose from the gastrointestinal tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biguanide Antidiabetic Agent","conceptCode":"C98234","definition":"Any antidiabetic agent with the biguanide base structure or phenformin derivatives with antihyperglycemic activity. Biguanide antidiabetic agents activate AMP-activated protein kinase (AMPK) resulting in decreased glucose production in the liver, increased peripheral glucose uptake and improved utilization of glucose. Biguanide-based antidiabetic agents do not cause hypoglycemia. In addition, biguanide antidiabetics decrease absorption of glucose from the gastrointestinal tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59A82CBF-6039-136A-E053-F662850A73DE","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59A82CBF-6052-136A-E053-F662850A73DE","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"ONEDATA","dateModified":"2017-09-20","deletedIndicator":"No"},{"value":"Injected Insulin","valueDescription":"Injectable Dosage Form Therapeutic Insulin","ValueMeaning":{"publicId":"5982800","version":"1","preferredName":"Injectable Dosage Form Therapeutic Insulin","longName":"5982800","preferredDefinition":"A substance intended for injection.: A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus. Therapeutic insulin is formulated to be short-, intermediate- and long-acting in order to individualize an insulin regimen according to individual differences in glucose and insulin metabolism. Therapeutic insulin may be derived from porcine, bovine or recombinant sources. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats and has anabolic effects on many types of tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Injectable Dosage Form","conceptCode":"C42946","definition":"A substance intended for injection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Insulin","conceptCode":"C581","definition":"A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus. Therapeutic insulin is formulated to be short-, intermediate- and long-acting in order to individualize an insulin regimen according to individual differences in glucose and insulin metabolism. Therapeutic insulin may be derived from porcine, bovine or recombinant sources. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats and has anabolic effects on many types of tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59A82CBF-605F-136A-E053-F662850A73DE","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59A82CBF-6078-136A-E053-F662850A73DE","beginDate":"2017-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-09-20","modifiedBy":"ONEDATA","dateModified":"2017-09-20","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3104212","version":"1","preferredName":"Unknown","longName":"3104212v1.00","preferredDefinition":"Not known, observed, recorded; or reported as unknown by the data contributor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F3C580-06F4-1DC3-E040-BB89AD434E7E","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":"Concept annotated for UPitt/TCGA.  Ylu, 01/30/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"641F1D08-A80F-538B-E053-F662850A0ACD","beginDate":"2018-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","deletedIndicator":"No"},{"value":"Insulin","valueDescription":"Therapeutic Insulin","ValueMeaning":{"publicId":"6059564","version":"1","preferredName":"Therapeutic Insulin","longName":"6059564","preferredDefinition":"A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus. Therapeutic insulin is formulated to be short-, intermediate- and long-acting in order to individualize an insulin regimen according to individual differences in glucose and insulin metabolism. Therapeutic insulin may be derived from porcine, bovine or recombinant sources. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats and has anabolic effects on many types of tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Insulin","conceptCode":"C581","definition":"A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus. Therapeutic insulin is formulated to be short-, intermediate- and long-acting in order to individualize an insulin regimen according to individual differences in glucose and insulin metabolism. Therapeutic insulin may be derived from porcine, bovine or recombinant sources. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats and has anabolic effects on many types of tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"641F1D08-A7E1-538B-E053-F662850A0ACD","latestVersionIndicator":"Yes","beginDate":"2018-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"641F1D08-A7FA-538B-E053-F662850A0ACD","beginDate":"2018-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","deletedIndicator":"No"},{"value":"Not Reported","valueDescription":"Not Reported","ValueMeaning":{"publicId":"2572231","version":"1","preferredName":"Not Reported","longName":"2572231","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E734-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-11-16","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"641F1D08-A804-538B-E053-F662850A0ACD","beginDate":"2018-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"641F1D08-A819-538B-E053-F662850A0ACD","beginDate":"2018-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3587241","version":"1","preferredName":"Diabetes Mellitus Therapeutic Procedure Type","preferredDefinition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Something distinguishable as an identifiable class based on common qualities.","longName":"C2985:C49236:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diabetes Mellitus","conceptCode":"C2985","definition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C91B83A2-A13F-517B-E040-BB89AD4321CE","latestVersionIndicator":"Yes","beginDate":"2012-09-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2012-09-07","modifiedBy":"ONEDATA","dateModified":"2012-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C91B83A2-A150-517B-E040-BB89AD4321CE","latestVersionIndicator":"Yes","beginDate":"2012-09-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2012-09-07","modifiedBy":"COOPERM","dateModified":"2018-01-31","changeDescription":"created for UAMS 9/7/12 cmr Added max length + PVs for HCMI reuse. 9.20.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3029677","version":"1","longName":"UAMS Clinical Research","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812848","version":"1","longName":"UAMS New CDEs","context":"NCIP"}]},{"publicId":"5428034","version":"1","longName":"Clinical","context":"GDC","ClassificationSchemeItems":[{"publicId":"6059563","version":"1","longName":"Followup","context":"GDC"}]},{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"5777527","version":"1","longName":"Pancreatic","context":"OCG"}]}],"AlternateNames":[{"name":"diabetes_treatment","type":"HCMI Name","context":"OCG"},{"name":"OCG","type":"USED_BY","context":"OCG"},{"name":"GDC","type":"USED_BY","context":"GDC"},{"name":"diabetes_treatment_type","type":"GDC_Name","context":"GDC"}],"ReferenceDocuments":[{"name":"Treatment","type":"Preferred Question Text","description":"Treatment","url":null,"context":"NCIP"},{"name":"HCMI Question Text","type":"Alternate Question Text","description":"Diabetes treatment","url":null,"context":"OCG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C91B83A2-A1C2-517B-E040-BB89AD4321CE","latestVersionIndicator":"Yes","beginDate":"2012-09-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2012-09-07","modifiedBy":"COOPERM","dateModified":"2018-01-31","changeDescription":"created for UAMS 9/7/12 cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}